

## SWL Commissioning Principles for PbR Excluded Drugs / Devices 2020-21

### Appendix 4: South West London (SWL) Commissioning Agreement for Insulin Pumps and Consumables

#### Background

Continuous subcutaneous insulin infusion (CSII) is often called 'insulin pump' therapy. The pump is a small device worn outside the body, which continuously delivers insulin into the body through a very thin tube or needle inserted under the skin. The insulin can be delivered at a set rate throughout the day, which can be increased when it is needed, for example at mealtimes.

#### Types of insulin pumps

There is a range of insulin pumps available, all delivering the same clinical benefits, but they vary in features and practical application. The annual cost is usually based on a four-year assumed life of the pump (pumps usually have a 4-year warranty). This policy does not cover integrated sensor-augmented pump therapy systems otherwise known as Continuous Glucose Monitoring (CGM) devices, although some of the insulin pumps available have the facility to be integrated with CGM.

#### Rationale

Previously SWL CCGs commissioned a limited range of insulin pumps based on relative costs. Recently, three pumps were discontinued by the manufacturer (limiting the range of pumps available in SWL) and new pumps entered the market. Commissioners need to ensure patients have access to a range of insulin pumps, giving clinicians/patients a choice based on the insulin pump features. However, there is also a need to manage the high costs of some of the newer pumps.

A price review of all currently available pumps was undertaken taking into account the Insulin Pump Procurement Framework for London, in order to refresh the current SWL commissioning agreement for insulin pumps. Clinicians from across SWL were involved and the proposal recommended by SWL Medicines Optimisation Group was approved by the SWL Directors of Commissioning group.

It was recommended that a standard charge be applied to all pumps and consumables, regardless of the pump in use to allow greater flexibility of pump use, but still helping to maintain expenditure.

#### Recommendations

All insulin pumps/consumables are available for NHS patients (adults and children) registered with CCGs in SWL, who meet NICE criteria and guidance agreed by the London clinical networks [1,2], which is evidence through submission of a "Funding Application for Insulin Pump (Package of Care) for Diabetes Mellitus type 1" or Tick Box Form (via Blueteq) on initiation and annually thereafter. The costs of insulin pumps will be reimbursed as follows, regardless of the pump in use (i.e. also applies to patch pumps):

- **Insulin pump consumables:** £170\* per patient per month starting from December 2019 SLAM/SLAM-PLD. This applies to both existing patients with funding approval in place and new patients starting insulin pump therapy.
- **Insulin pump:** One-off £3000\* for each newly initiated pump. This is to be charged once every 4 years for each patient (based on a four-year assumed life/warranty of the pump).

Charges should be submitted through SLAM and SLAM-PLD as follows:

Insulin pump name – insulin pump consumables: £170\*  
 Insulin pump name – insulin pump £3000\*

E.g.

Accucheck combo – insulin pump consumables £170\*  
 Accucheck combo– insulin pump £3000\*

The financial implications of this arrangement will be audited in 6 months' time and is therefore subject to change.

Version	Approved by:	Date of approval:
1.0	SWL Medicines Optimisation Group SWL CCG Directors of Commissioning	04 October 2019 25 October 2019

#### Authors:

Louise Coughlin, Joint Chief Pharmacist, Croydon University Hospital and Croydon CCG  
 Rajiv Dhir, Deputy Chief Pharmacist- Merton and Wandsworth CCGs  
 Brigitte van der Zanden, SWL Lead Commissioning Pharmacist, NEL CSU

11 December 2019

#### References:

1. South East Coast and London Paediatric Diabetes Network. Guidance on Insulin Pumps and Continuous Glucose Monitoring (CGM) for children and young people. July 2018
2. London Diabetes Clinical Network and NHS London Procurement Partnership. London Guidance: Recommended Commissioning Arrangements for CSII or Insulin Pumps in Adults with Type 1 Diabetes. 20 September 2018 (version 1.0)

#### Addendum:

Trusts can claim retrospective funding if patients meet all above requirements for the following scenarios:

- Patients that required a new, previously unapproved, pump due to the discontinuation of their regular pump (which was still in warranty) since May 2019:
  - Insulin pump consumables: £170\* / month
  - Insulin pump: £3000\* minus any rebates/discounts received as a result of the discontinued pump (unless there is a pre-arranged local agreement)
- Patients who required a new pump from September 2019 which was approved via the IFR process and not yet claimed via SLAM/SLAM-PLD or otherwise:
  - Insulin pump consumables: £170\* / month
  - Insulin pump: £3000\*

\*All quoted prices include VAT